Trust Signals
- All mechanism numbers cite named published studies, not secondary sources.
- Evidence grades are assigned conservatively. Lab findings are not presented as clinical outcomes.
- Competitive alternatives, including approved drugs, are compared honestly and the peptide loses where it should.
- No affiliate ranking. Order reflects evidence quality, not commercial relationships.
- Research compound status and legal context are disclosed, not buried.
Key Takeaways
- CJC-1295 with DAC produced sustained GH elevation over 6 days in the Teichman et al. (2006) human dose-escalation study, the strongest pharmacokinetic dataset for any GHRH analog in this class.
- Ipamorelin's selectivity for GHS-R1a without significant cortisol or prolactin elevation makes it mechanistically preferable to GHRP-2 and GHRP-6, though all three lack lean-mass RCTs in healthy adults.
- No research peptide has an approved human RCT demonstrating statistically significant lean mass gain in healthy, well-nourished, resistance-trained adults. The anabolic case rests on GH/IGF-1 elevation, not direct body composition endpoints.
- MK-677 is the only ghrelin-pathway compound with a published RCT showing lean body mass gains (Svensson et al. 1998, Nass et al. 2008), but it is a small molecule, not a peptide.
- Peptide purity matters clinically: a 95% pure vial contains 5% unknown impurities; independent HPLC plus mass spec COAs are the minimum acceptable quality standard.
What Are the Best Bulking Peptides?
Table of Contents
- The Ranked List: 5 Best Bulking Peptides
- Evidence Ledger Table
- How GH Secretagogues Drive Anabolism: Specific Numbers
- What Most Pages Get Wrong About Bulking Peptides
- The Chemistry Behind Storage and Stability Rules
- Honest Head-to-Head: Peptides vs Real Alternatives
- How to Read a COA and Reconstitute Correctly
- Do Stacks Work? GHRH Plus GHRP Protocols
- FAQ
- Sources
Which Peptides Are Actually Best for Bulking?
1. CJC-1295 with DAC Moderate Evidence
Class: GHRH analog. Receptor target: GHRH receptor (GHRHR) on pituitary somatotrophs. Half-life: Approximately 6 to 8 days with DAC modification vs roughly 30 minutes for unmodified CJC-1295.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The Teichman et al. (2006) phase I/II trial in 65 healthy adults showed dose-dependent GH and IGF-1 increases with single subcutaneous doses of 30 to 60 mcg/kg, with IGF-1 elevation persisting for up to 28 days at higher doses. This is the most rigorous human pharmacokinetic dataset for any GHRH analog in this class. Lean mass was not a primary endpoint.
Best use case: Low-frequency dosing protocols (once or twice weekly) where sustained GH elevation is the goal. Trade-off: Non-pulsatile GH may reduce natural GH axis feedback sensitivity over extended use.
2. Ipamorelin Moderate Evidence
Class: Selective GHRP (growth hormone releasing peptide). Receptor target: GHS-R1a. Half-life: Approximately 2 hours.
Ipamorelin was characterized in Johansen et al. (1999) and multiple subsequent animal studies as the most selective GHRP, producing GH release without statistically significant cortisol or prolactin elevation at therapeutic doses, a distinction from GHRP-2 and GHRP-6. Human dose-finding data exist but large-scale lean-mass RCTs do not.
Best use case: Frequent pulsatile dosing (2 to 3 times daily) to mimic physiologic GH pulsatility. Often stacked with CJC-1295 without DAC for synergistic GH release. Trade-off: Requires frequent injections; shortest action window of the three main GHRPs.
3. GHRP-2 (Pralmorelin) Moderate Evidence
Class: GHRP. Receptor target: GHS-R1a plus possible GHRHR cross-activation. Half-life: Approximately 20 to 30 minutes.
GHRP-2 has a larger human pharmacology dataset than Ipamorelin, including diagnostic use in Japan (approved as Pralmorelin for GH deficiency testing). Studies including Arvat et al. (1997) confirm robust GH stimulation. GHRP-2 also elevates ACTH and cortisol at higher doses, which matters for prolonged bulking protocols where cortisol is a concern.
Best use case: Users tolerating mild cortisol elevation who want strong GH pulse amplitude. Trade-off: Cortisol and prolactin co-stimulation at doses above roughly 100 mcg.
4. GHRP-6 Low-to-Moderate Evidence for Bulking
Class: GHRP. Receptor target: GHS-R1a. Half-life: Approximately 15 to 25 minutes.
GHRP-6 was among the earliest synthetic GHRPs studied and has substantial GH stimulation data (Laron et al., 1995). Its main distinguishing feature for bulking is potent appetite stimulation via ghrelin pathway activation, which can support caloric surplus. However, the same mechanism causes pronounced hunger and can make dietary control harder. Cortisol elevation similar to GHRP-2.
Best use case: Calorie-restricted or low-appetite individuals who struggle to hit caloric targets. Trade-off: Appetite effect can overshoot; ghrelin-mediated fat deposition signal is the opposite of recomposition.
5. BPC-157 (Recovery Support) Very Low Evidence for Direct Anabolism
Class: Synthetic pentadecapeptide derived from gastric protein. Receptor target: Not fully characterized; involves VEGFR2 and nitric oxide pathways in animal studies. Half-life: Not established in humans.
BPC-157 has no published human RCT for any indication as of 2026. All structural repair and tendon healing data come from rodent models. Its inclusion on bulking lists is indirect: injury prevention and faster tendon/ligament recovery may allow higher training volume. There is no mechanism or data supporting direct myofibrillar hypertrophy.
Best use case: Recovery support during high-volume training phases. Trade-off: No human evidence at all; animal-to-human translation unvalidated.
Evidence Ledger: Every Major Bulking Claim Graded
| Peptide | Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|---|
| CJC-1295 w/ DAC | Elevates GH and IGF-1 in healthy adults | Human pharmacokinetic study (Teichman et al., 2006, n=65) | Positive, dose-dependent | Moderate |
| CJC-1295 w/ DAC | Increases lean body mass | Mechanism inference only (no lean-mass RCT) | Unproven in healthy adults | Very Low |
| Ipamorelin | Selective GH release without cortisol spike | Animal and early human pharmacology (Johansen et al., 1999) | Positive for selectivity | Moderate |
| GHRP-2 | Stimulates GH release in adults | Multiple human studies including Arvat et al. (1997) | Positive | High (for GH effect) |
| GHRP-2 | Elevates cortisol and prolactin | Human pharmacology studies | Positive (undesirable) | High |
| GHRP-6 | Appetite stimulation via ghrelin pathway | Human and animal studies | Positive | Moderate |
| BPC-157 | Tendon/ligament repair | Rodent models only (no human RCT) | Positive in animals | Very Low (for humans) |
| MK-677 (reference) | Lean mass increase in older adults | Human RCT (Nass et al., 2008; Svensson et al., 1998) | Positive | Moderate |
| Any GH secretagogue | Muscle hypertrophy in healthy, trained adults | No adequate RCT exists for peptides | Unproven | Very Low |
How Do GH Secretagogues Actually Drive Anabolism? Specific Numbers
The core pathway: GHRH analogs (CJC-1295) bind the GHRHR on pituitary somatotrophs, increasing intracellular cAMP, which triggers GH pulse release. GHRPs (Ipamorelin, GHRP-2) activate GHS-R1a, increasing intracellular calcium and amplifying GH pulse amplitude. The two classes act synergistically through different second-messenger systems.
GH then stimulates hepatic IGF-1 synthesis. Circulating IGF-1 binds IGF1-R on skeletal muscle, activating the PI3K/Akt/mTOR pathway, which promotes protein synthesis and inhibits protein catabolism via FOXO transcription factor suppression. This is a real and well-characterized pathway.
What the numbers show: Teichman et al. (2006) reported that a 60 mcg/kg dose of CJC-1295 with DAC produced mean IGF-1 increases of roughly 2 to 3 times baseline over the following week. Arvat et al. (1997) showed GHRP-2 at 1 mcg/kg IV produced GH peaks of approximately 30 to 60 ng/mL, compared to baseline levels typically under 3 ng/mL in resting adults.
What the numbers do NOT prove: Supraphysiologic GH and IGF-1 elevations in healthy adults with intact GH axes do not reliably translate to lean mass gain in controlled trials. Multiple meta-analyses of exogenous recombinant GH in healthy adults (Liu et al., 2007 in Annals of Internal Medicine) found modest or no lean mass benefit at realistic doses, with meaningful adverse effect rates. Peptides stimulate endogenous GH; they likely produce lower absolute GH elevations than exogenous GH injection, not higher ones, which sets a ceiling on their anabolic potential.
What Most Bulking Peptide Pages Get Wrong
The CJC-1295 naming confusion: Most vendors sell "CJC-1295 without DAC" which is actually Modified GRF(1-29), a different compound. True CJC-1295 refers specifically to the DAC-modified version. This naming error proliferates across nearly every peptide blog and creates dosing confusion, because the two compounds have radically different half-lives and dosing schedules.
The purity problem: Research peptides sold in the gray market are not pharmaceutical grade. A COA showing 95% purity means 5% of the vial content is unknown. For a 2 mg vial, that is 100 mcg of uncharacterized material being injected. Independent HPLC purity combined with mass spectrometry for identity confirmation is the minimum standard a credible supplier should provide. Many do not.
The endotoxin omission: Bacterial endotoxin contamination in improperly synthesized peptides causes inflammation and flu-like injection reactions. Endotoxin testing (LAL test) should appear on any COA for injectable peptide products. Most consumer-facing vendors omit it entirely.
Why Do Storage Rules Actually Matter? The Chemistry
Peptides degrade through specific chemical pathways, not just vague "breakdown." Understanding these lets you make real storage decisions.
Lyophilized (freeze-dried) peptide: Stored in a vacuum or inert gas at minus 20 degrees Celsius, most peptides remain stable for 1 to 2 years because the absence of water prevents hydrolysis (peptide bond cleavage by water). Heat accelerates hydrolysis even in dry powder; repeated freeze-thaw cycles also degrade fragile bonds.
After reconstitution with bacteriostatic water: Water is now present. Hydrolysis begins slowly. Temperature matters because hydrolysis rate approximately doubles with every 10 degrees Celsius increase (the Arrhenius relationship). At 4 degrees Celsius (refrigerator), most linear peptides remain substantially intact for 2 to 4 weeks. At room temperature (approximately 22 degrees Celsius), degradation is meaningfully faster. Ultraviolet light drives oxidation of methionine and cysteine residues, which is why opaque or amber vials matter.
Why bacteriostatic water, not sterile water: Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth for multi-dose use. Sterile water has no preservative and becomes contaminated after the first puncture. This is not optional hygiene; contaminated reconstituted peptide presents infection and endotoxin risk with every subsequent injection.
The pH issue: Most GHRH and GHRP peptides are stable near neutral pH. Reconstituting with highly acidic solutions (such as acetic acid, sometimes recommended for insoluble peptides like some growth factors) can cleave acid-labile peptide bonds in susceptible sequences. CJC-1295 and standard GHRPs dissolve readily in bacteriostatic water and do not require acidic reconstitution.
Honest Head-to-Head: Bulking Peptides vs Real Alternatives
| Compound | Mechanism | Human Lean Mass Evidence | Practical Anabolic Effect (Healthy Adults) | Risk Profile | Legal/Approval Status |
|---|---|---|---|---|---|
| CJC-1295 + Ipamorelin stack | GHRHR + GHS-R1a stimulation | None (no lean-mass RCT) | Low to modest (theoretical) | Fluid retention, insulin resistance at high doses; long-term axis effects unclear | Not FDA-approved; WADA banned |
| MK-677 (Ibutamoren) | Oral GHS-R1a agonist | RCTs showing lean mass in elderly/GHD; modest in healthy | Low to modest | Fasting glucose elevation, insulin resistance, edema | Not FDA-approved; WADA banned |
| Recombinant Human GH (rHGH) | Direct GH receptor activation | RCT data; modest lean mass in adults, stronger in GHD | Modest (healthy adults); meaningful (GHD) | Edema, carpal tunnel, insulin resistance, IGF-1-driven cancer risk concern long-term | FDA-approved for GHD; off-label use for bulking is illegal |
| Testosterone (exogenous) | Androgen receptor activation in muscle | Multiple RCTs showing dose-dependent lean mass gains | High (clearly superior) | Axis suppression, cardiovascular, erythrocytosis, androgenic effects | FDA-approved for hypogonadism; off-label use common |
| Creatine monohydrate | PCr resynthesis, cell hydration | Extensive RCTs (ISSN position stand) | Modest but consistent and proven | Very low; mild GI at high doses | Legal supplement, no ban |
Honest verdict: For lean mass in healthy adults, testosterone has the strongest evidence base by a wide margin. Creatine has more RCT support for practical hypertrophy than any peptide in this list. Bulking peptides occupy a mechanistically plausible but clinically unproven middle space between proven supplements and approved drugs.
How to Read a Peptide COA and Reconstitute Correctly
Reading a Certificate of Analysis
A credible peptide COA from an independent third-party laboratory should contain:
- Lot number matching your vial (generic COAs not tied to a specific lot are meaningless)
- HPLC purity percentage with chromatogram (above 98% is the accepted research-grade threshold)
- Molecular mass confirmation by mass spectrometry (confirms identity, not just purity)
- Endotoxin level by LAL (limulus amebocyte lysate) test; typically acceptable below 5 EU/mg for research use
- Testing laboratory name and accreditation (ISO 17025 or equivalent)
Red flags: in-house testing only, no mass spec, no lot-specific data, PDF that looks templated with no instrument data.
Reconstitution Math
Standard example: 2 mg lyophilized peptide vial.
- Add 2 mL of bacteriostatic water to get a 1 mg/mL (1000 mcg/mL) solution.
- Add 1 mL of bacteriostatic water to get a 2 mg/mL (2000 mcg/mL) solution.
- A typical research dose of 100 mcg from a 1 mg/mL solution requires 0.1 mL, which is the 10-unit line on a standard U-100 insulin syringe.
- Always inject bacteriostatic water slowly down the vial wall, not directly onto the lyophilized cake, to avoid shearing peptide bonds through turbulence.
What Degraded Peptide Looks Like
Properly reconstituted peptides are colorless and clear. Yellow or brown discoloration after reconstitution suggests oxidation. Cloudiness or particulates after reconstitution in bacteriostatic water may indicate aggregation or microbial contamination. Discard any reconstituted vial showing these signs. A vial left at room temperature for days and then refrigerated is not recoverable to full potency.
Do Stacks Work? The GHRH Plus GHRP Protocol
Combining a GHRH analog (CJC-1295) with a GHRP (Ipamorelin) is the most common bulking peptide stack and it has genuine mechanistic rationale. The two classes act on different receptors through different intracellular pathways (cAMP for GHRHR, intracellular calcium for GHS-R1a), producing greater GH pulse amplitude than either alone. Studies in this area, including Walker et al. (1995) in animal models and subsequent human pharmacology work, confirm the synergistic effect on GH release.
The honest limitation: Greater GH pulse height does not linearly translate to more muscle. Supraphysiologic GH chronically elevates IGF-1 beyond the range that confers incremental anabolic benefit, while increasing the risk of insulin resistance, soft tissue edema, and potential long-term somatotroph downregulation.
Receptor desensitization: GHS-R1a desensitizes with chronic high-frequency activation. Most research protocols cycle peptides (for example, 5 days on, 2 days off, or 8 to 12 week cycles with equal breaks) partly to address this, though the optimal cycling strategy has not been studied in humans.
Frequently Asked Questions
What are the best bulking peptides for muscle gain?
CJC-1295 with DAC, Ipamorelin, and GHRP-2 have the most human evidence for GH and IGF-1 elevation relevant to anabolism. MK-677 (ibutamoren) is technically a non-peptide ghrelin mimetic but produces similar outcomes. BPC-157 and TB-500 are recovery-support peptides, not direct anabolics.
Do bulking peptides actually build muscle or just raise GH?
GH secretagogues reliably raise GH and IGF-1 in human studies. Whether that translates to lean mass gain in healthy, well-nourished adults is less clear; the clearest lean-mass signal in RCTs is in GH-deficient or elderly populations, not young healthy bodybuilders.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC (Drug Affinity Complex) covalently binds albumin, extending the half-life from roughly 30 minutes to approximately 6 to 8 days. This allows once or twice weekly dosing but produces a sustained, non-pulsatile GH elevation that may blunt natural pulsatility over time.
How does Ipamorelin differ from GHRP-2 and GHRP-6?
Ipamorelin is highly selective for the GHS-R1a receptor and produces minimal cortisol or prolactin elevation, unlike GHRP-2 which raises both, and GHRP-6 which causes significant appetite stimulation and ghrelin-mediated hunger. Ipamorelin is considered the cleaner option with a narrower side-effect profile.
Is MK-677 a peptide?
No. MK-677 (ibutamoren) is a non-peptide, orally active ghrelin mimetic that activates the GHS-R1a receptor. It is often grouped with bulking peptides because it mimics ghrelin and raises GH and IGF-1, but it is a small molecule, not a peptide.
What dose of CJC-1295 with DAC is used in research?
The Teichman et al. (2006) human pharmacology study used single doses of 30 to 60 mcg/kg subcutaneously, producing dose-dependent GH increases. Common research protocols adapt these to fixed doses of roughly 1 to 2 mg per injection one to two times per week, though no lean-mass RCT has validated a specific dosing schedule.
Can peptides replace anabolic steroids for bulking?
No. Anabolic steroids directly activate androgen receptors in muscle tissue and produce lean mass gains that are substantially larger in magnitude and faster in onset than anything demonstrated for GH secretagogue peptides in healthy adults. Peptides do not carry the same androgenic risk profile, but they are not equivalent in anabolic effect.
What does BPC-157 actually do for bulking?
BPC-157 is a gastric pentadecapeptide studied primarily for tissue repair, tendon healing, and gut mucosal recovery in rodent models. It has no direct anabolic mechanism. Its relevance to bulking is indirect: faster injury recovery may allow more consistent training volume. Human RCT data for BPC-157 are currently absent.
How do I know if a research peptide is pure?
Reputable suppliers provide a Certificate of Analysis (COA) from an independent third-party lab showing HPLC purity (ideally above 98%), mass spectrometry identity confirmation, and endotoxin testing. Avoid vendors that supply only in-house COAs or whose documents lack the specific lot number matching your vial.
How should bulking peptides be stored?
Lyophilized (freeze-dried) peptides should be stored at minus 20 degrees Celsius long-term and at 2 to 8 degrees Celsius for short-term use up to a few weeks. Once reconstituted in bacteriostatic water, most peptides are stable at refrigerator temperature for roughly 2 to 4 weeks before significant degradation occurs. Light and heat accelerate oxidation of methionine and cysteine residues.
Are bulking peptides legal?
In the United States, most research peptides are not FDA-approved drugs and are sold legally only as research chemicals, not for human use. GHRP-2, GHRP-6, Ipamorelin, and CJC-1295 are on the WADA Prohibited List under the category of peptide hormones and growth factors, banning their use in competitive sport.
What is the biggest mistake people make when stacking bulking peptides?
The most common mistake is combining a GHRH analog (like CJC-1295) with a GHRP (like Ipamorelin) without accounting for receptor desensitization from excessive GH stimulation, and ignoring that supraphysiologic GH elevation over time can cause insulin resistance, joint fluid retention, and car
Related peptide guides
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →